Tumor markers Tumor markers| Marker | Cancer Type | Gene | Glycan |
| ALK gene rearrangements | Non-small cell lung cancer [DS:H00014] Anaplastic large cell lymphoma [DS:H01601] |
EML4-ALK fusion gene TFG-ALK fusion gene KIF5B-ALK fusion gene NPM-ALK fusion gene |
|
| Alpha-fetoprotein (AFP) | Liver cancer [DS:H00048] Germ cell tumors [DS:H00023] |
AFP | |
| Beta-2-microglobulin (B2M) | Multiple myeloma [DS:H00010] Chronic lymphocytic leukemia [DS:H00005] Some lymphomas [DS:H00011] |
B2M | |
| Beta-human chorionic gonadotropin (Beta-hCG) | Choriocarcinoma [DS:H00028] Germ cell tumors [DS:H00023] |
CGB | |
| BRCA1 and BRCA2 gene mutations | Ovarian cancer [DS:H00027] | BRCA1 BRCA2 |
|
| BCR-ABL fusion gene | Chronic myeloid leukemia [DS:H00005] Acute lymphoblastic leukemia [DS:H00001 H00002] Acute myelogenous leukemia [DS:H00003] |
ABL1 BCR |
|
| BRAF mutation V600E | Cutaneous melanoma [DS:H00038] Colorectal cancer [DS:H00020] |
BRAF mutation V600E | |
| CA15-3/CA27.29 | Breast cancer [DS:H00031] | MUC1 | G00242 |
| CA19-9 | Pancreatic cancer [DS:H00019] Gallbladder cancer [DS:H00047] Bile duct cancer [DS:H00046] Gastric cancer [DS:H00018] |
G12794 | |
| CA125 | Ovarian cancer [DS:H00027] | MUC16 (CA125) | |
| Calcitonin | Medullary thyroid cancer [DS:H01592] | CALCA | |
| Carcinoembryonic antigen (CEA) | Colorectal cancer [DS:H00020] Some other cancers [DS:H00018 H00019 H00014 H00031] |
CEACAM1 | |
| CD20 | Non-Hodgkin lymphoma [DS:H00011 H00006 H01613 H01464 H00008] | MS4A1 | |
| Chromogranin A (CgA) | Neuroendocrine tumors [DS:H00034 H00045] | CHGA | |
| Chromosomes 3, 7, 17 and, 9p21 | Bladder cancer [DS:H00022] | ||
| Circulating tumor cells of epithelial origin | Metastatic breast cancer [DS:H00031] Metastatic prostate cancer [DS:H00024] Metastatic colorectal cancer [DS:H00020] |
||
| Cytokeratin fragments 21-1 (Cyfra 21-1) | Lung cancer [DS:H00013 H00014] | KRT19 | |
| EGFR mutation analysis | Non-small cell lung cancer [DS:H00014] | EGFR | |
| Estrogen receptor (ER) / progesterone receptor (PR) | Breast cancer [DS:H00031] | ESR1, ESR2 PGR |
|
| Fibrin/fibrinogen | Bladder cancer [DS:H00022] | FGA, FGB, FGG | |
| HE4 | Ovarian cancer [DS:H00027] | WFDC2 | |
| HER2/neu gene amplification or protein overexpression | Breast cancer [DS:H00031] Gastric cancer [DS:H00018] Gastroesophageal junction adenocarcinoma |
ERBB2 (HER2) | |
| Immunoglobulins | Multiple myeloma [DS:H00010] Waldenström macroglobulinemia [DS:H00011] |
||
| KIT | Gastrointestinal stromal tumor Mucosal melanoma |
KIT | |
| KRAS mutation analysis | Colorectal cancer [DS:H00020] Non-small cell lung cancer [DS:H00014] |
KRAS | |
| Lactate dehydrogenase | Germ cell tumors [DS:H00023] Lymphoma Leukemia [DS:H00005 H00009] Melanoma [DS:H00038] Neuroblastoma [DS:H00043] |
LDHA, LDHB, LDHC | |
| Neuron-specific enolase (NSE) | Small cell lung cancer [DS:H00013] Neuroblastoma [DS:H00043] |
NSE | |
| Nuclear matrix protein 22 | Bladder cancer [DS:H00022] | NUMA1 | |
| Programmed death ligand 1 (PD-L1) | Non-small cell lung cancer [DS:H00014] | PD-L1 | |
| Prostate-specific antigen (PSA) | Prostate cancer [DS:H00024] | KLK3 | |
| Thyroglobulin | Thyroid cancer [DS:H00032] | TG | |
| Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) | Breast cancer [DS:H00031] | PLAU SERPINE1 |
|
| 5-Protein signature (Ova1) | Ovarian cancer [DS:H00027] | APOA1, B2M, MUC16, TTR, TF | |
| 21-Gene signature (Oncotype DX) | Breast cancer [DS:H00031] | MKI67, AURKA, BIRC5, CCNB1, MYBL2, MMP11, CTSV, GRB7, ERBB2, GSTM1, CD68, BAG1, ESR1, PGR, BCL2, SCUBE2, ACTB, GAPDH, RPLP0, GUSB, TFRC |
|
| 70-Gene signature (Mammaprint) | Breast cancer [DS:H00031] |